Klor-Con/Ef (Potassium Bicarbonate)
Brand Names: Klor-Con/Ef
Methodology & AI Transparency ⓘ
Klor-Con/Ef (Potassium Bicarbonate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Osmotic Laxative category, Klor-Con/Ef provides branded delivery of active moiety Potassium Bicarbonate (cross-referenced at /meds/potassium-bicarbonate) (registered by Upsher-Smith Laboratories, Inc.; NDC 0245-5326).
- 2 Real-world patient consensus: Registered under RxNorm RXN-B02455326 and SPL 2019-12-18, pairing Klor-Con/Ef packaging with active ingredient Potassium Bicarbonate.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $70.38 cash mean against $186.51 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Klor-Con/Ef (Potassium Bicarbonate): nausea (10.4%), diarrhea (7.7%), vomiting (4%).
Ask our AI Specialists anything about Klor-Con/Ef (Potassium Bicarbonate)
Klor-Con/Ef (Potassium Bicarbonate) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Osmotic Laxative category, Klor-Con/Ef provides branded delivery of active moiety Potassium Bicarbonate (cross-referenced at /meds/potassium-bicarbonate) (registered by Upsher-Smith Laboratories, Inc.; NDC 0245-5326). Characterized by 978 mg/1 Tablet, Effervescent; 978 mg/1 Tablet under 2019-12-18 SPL documentation, Klor-Con/Ef targets For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication;.
Through its Potassium Bicarbonate active moiety, Klor-Con/Ef exerts osmotic laxative activity with class-characteristic hepatorenal disposition. Registered under NDC 0245-5326 (registered by Upsher-Smith Laboratories, Inc.; effective 2019-12-18), the 978 mg/1 Tablet, Effervescent; 978 mg/1 Tablet presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (RXN-B02455326) and CMS NADAC ($0.8594/unit) ledgers.
With Depot mucosal/cutaneous persistence without significant systemic accumulation of Klor-Con/Ef (Potassium Bicarbonate) residence kinetics and < 5% transdermal or mucosal systemic uptake from Klor-Con/Ef (Potassium Bicarbonate) bioavailability, Klor-Con/Ef (Potassium Bicarbonate) undergoes local esterase/enzymatic cleavage of klor-con/ef (potassium bicarbonate) with minimal hepatic cytochrome burden and establishes therapeutic activity over initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (klor-con/ef (potassium bicarbonate)).
Standard adult regimens span 978 mg/1 Tablet, Effervescent, 978 mg/1 Tablet. Prescribers screen specifically against severe drug-induced hypersensitivity to potassium bicarbonate or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2019-12-18 for klor-con/ef (potassium bicarbonate), while community micro-logs most frequently note nausea (10.4% of reports), diarrhea (7.7% of reports), application-site erythema (6.6% of reports).
Check serum potassium and creatinine periodically if Klor-Con/Ef (Potassium Bicarbonate) is co-administered with potassium-retaining agents.
Assess baseline hepatic panels and interacting prescriptions when starting Klor-Con/Ef (Potassium Bicarbonate) (osmotic laxative).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Potassium Bicarbonate or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2019-12-18 for Klor-Con/Ef (Potassium Bicarbonate)
Logged Side-Effect Incidence (20 Reports)
Klor-Con/Ef (Potassium Bicarbonate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Klor-Con/Ef (Potassium Bicarbonate))
Human clinical trial evidence for Klor-Con/Ef (Potassium Bicarbonate) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Klor-Con/Ef (Potassium Bicarbonate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.8594/unit (~$25.78/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $186.51 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $70.38 / mo | View logs ↓ |
Klor-Con/Ef (Potassium Bicarbonate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Klor-Con/Ef (Potassium Bicarbonate) RxNorm Concept ID | RXN-B02455326 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.8594 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $186.51 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $70.38 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Klor-Con/Ef (Potassium Bicarbonate) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Klor-Con/Ef (Potassium Bicarbonate) (osmotic laxative) monograph synthesizing RxNorm RXN-B02455326, openFDA FAERS signals, and $70.38–$186.51 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Klor-Con/Ef (Potassium Bicarbonate) community threads and patient logs by age, biological sex, dosage, and treatment duration.